Martin Driscoll
Chairman chez RIGImmune, Inc.
Profil
Martin J.
Driscoll was the founder and had founded Pear Tree Pharmaceuticals, Inc. in 2007, where he served as the Chief Executive Officer.
He is currently the Chairman at RIGImmune, Inc. and the Director at The Barn for the Poorest of the Poor.
In his former positions, Mr. Driscoll was the Chief Executive Officer & Director at Javelin Pharmaceuticals, Inc. from 2008 to 2010.
He also served as the President, Chief Executive Officer & Director at F-Star Therapeutics, Inc. (United States) from 2019 to 2020, and as the Chief Executive Officer & Director at OncoNano Medicine, Inc. from 2021 to 2024.
Additionally, he held positions as a Director at Genta, Inc., Asmacure Ltée, and MetaStat, Inc. He was the Vice President-Sales & Marketing at Schering-Plough Corp.
from 1983 to 2000, and the VP-Commercial Operations & Business Development at Shire ViroPharma, Inc. from 2000 to 2002.
He also served as the Senior Vice President-Sales & Marketing at Reliant Pharmaceuticals LLC from 2003 to 2005.
Mr. Driscoll has also worked as a Principal at MJD Consulting LLC and as the President at MKD Consulting, Inc. He was a Partner at Tgas Consulting LLC in 2007.
Mr. Driscoll obtained his undergraduate degree from The University of Texas at Austin.
Postes actifs de Martin Driscoll
| Sociétés | Poste | Début |
|---|---|---|
| The Barn for the Poorest of the Poor | Director/Board Member | - |
RIGImmune, Inc.
 RIGImmune, Inc. Miscellaneous Commercial ServicesCommercial Services RIGImmune, Inc. is a platform biopharmaceutical company based in Farmington, CT, with subsidiaries in the United Kingdom. The company is developing a novel investigational class of RNA immunotherapies called "SLRs" for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The lead development candidate at RIGImmune is RIG-101, which specifically modulates RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The company was founded in 2020 by Akiko Iwasaki and Anna Marie Pyle, both prominent Yale University professors who currently serve as scientific advisors to the company. | Chairman | - |
Anciens postes connus de Martin Driscoll
| Sociétés | Poste | Fin |
|---|---|---|
OncoNano Medicine, Inc.
 OncoNano Medicine, Inc. BiotechnologyHealth Technology OncoNano Medicine, Inc. operates as a biotechnology company. It develops pH-activated compounds that digitalize and exploit the variability of pH in disease. The company was founded by Ravi Srinivasan, Jinming Gao, and Baran Sumer in 2014 and is headquartered in Southlake, TX. | Chief Executive Officer | 01/03/2024 |
| SPRING BANK PHARMACEUTICALS, INC. | Chief Executive Officer | 20/11/2020 |
| METASTAT, INC. | Director/Board Member | 25/04/2017 |
Javelin Pharmaceuticals, Inc.
 Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | Chief Executive Officer | 01/07/2010 |
Genta, Inc.
 Genta, Inc. Pharmaceuticals: MajorHealth Technology Genta, Inc. is in the process of bankruptcy. The company formerly engages in pharmaceutical research and development. Genta was founded on February 4, 1988 and is headquartered in Berkeley Heights, NJ. | Director/Board Member | 26/08/2009 |
Formation de Martin Driscoll
| The University of Texas at Austin | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| METASTAT, INC. | Producer Manufacturing |
| Entreprise privées | 14 |
|---|---|
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
Shire ViroPharma, Inc.
 Shire ViroPharma, Inc. Pharmaceuticals: MajorHealth Technology Shire ViroPharma, Inc. develops and manufactures drugs. It offers treatment for prophylaxis of hereditary angioedema, as well as capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis. The company was founded by Claude H. Nash and Mark A. McKinlay in September 1994 and is headquartered in Exton, PA. | Health Technology |
Reliant Pharmaceuticals LLC
 Reliant Pharmaceuticals LLC Miscellaneous Commercial ServicesCommercial Services Reliant Pharmaceuticals, Inc. sells, markets and develops cardiovascular pharmaceutical products. The company focuses on marketing promotionally sensitive pharmaceutical products to the primary care, cardiovascular and specialist physician markets in the United States. The company is headquartered in Liberty Corner, NJ | Commercial Services |
Genta, Inc.
Genta, Inc. Pharmaceuticals: MajorHealth Technology Genta, Inc. is in the process of bankruptcy. The company formerly engages in pharmaceutical research and development. Genta was founded on February 4, 1988 and is headquartered in Berkeley Heights, NJ. | Health Technology |
Pear Tree Pharmaceuticals, Inc.
 Pear Tree Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Pear Tree Pharmaceuticals, Inc. operates as a development stage company with interests in developing prescription products for women. It offers products that treat and prevent diseases, symptoms, and conditions associated with menopause and cancer chemotherapy. The company was founded by Stephen Charles Rocamboli, Fred H. Mermelstein, Janet Chollet and Martin J. Driscoll in July 2007 and is headquartered in Auburndale, MA. | Health Technology |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | Health Technology |
Asmacure Ltée
 Asmacure Ltée Pharmaceuticals: MajorHealth Technology Asmacure Ltée develops novel, proprietary compounds that target cholinergic receptors for the treatment of inflammation, notably pulmonary airway diseases. The company was founded by Yvon Cormier and Evelyne Israel-Assayag in 2002 and is headquartered in Quebec, Canada. | Health Technology |
| MJD Consulting LLC | |
| MKD Consulting, Inc. | |
F-Star Therapeutics, Inc. (United States)
 F-Star Therapeutics, Inc. (United States) Pharmaceuticals: MajorHealth Technology F-Star Therapeutics, Inc. engages in discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. Its products are used for the treatment of viral infections, inflammatory diseases, and certain cancers. The company was founded by Douglas J. Jensen and Radhakrishnan P. Iyer on October 7, 2002 and is headquartered in Hopkinton, MA. | Health Technology |
| The Barn for the Poorest of the Poor | |
| Tgas Consulting LLC | |
OncoNano Medicine, Inc.
OncoNano Medicine, Inc. BiotechnologyHealth Technology OncoNano Medicine, Inc. operates as a biotechnology company. It develops pH-activated compounds that digitalize and exploit the variability of pH in disease. The company was founded by Ravi Srinivasan, Jinming Gao, and Baran Sumer in 2014 and is headquartered in Southlake, TX. | Health Technology |
RIGImmune, Inc.
RIGImmune, Inc. Miscellaneous Commercial ServicesCommercial Services RIGImmune, Inc. is a platform biopharmaceutical company based in Farmington, CT, with subsidiaries in the United Kingdom. The company is developing a novel investigational class of RNA immunotherapies called "SLRs" for the potential pan-viral treatment and prophylaxis of viral respiratory diseases and selected cancers. The lead development candidate at RIGImmune is RIG-101, which specifically modulates RIG-I, a host surveillance pathway that triggers the innate immune system to enhance an intrinsic response to RNA viruses, including influenza, RSV, rhinovirus, and SARS-CoV-2, and tumor DNA. The company was founded in 2020 by Akiko Iwasaki and Anna Marie Pyle, both prominent Yale University professors who currently serve as scientific advisors to the company. | Commercial Services |
